

H30-A2
Vol. 21 No. 18

Replaces H30-A
Vol. 14 No. 2

Procedure for the Determination of Fibrinogen in Plasma;
Approved Guideline—Second Edition

This document provides guidance on performing the fibrinogen assay in the clinical laboratory. Topics addressed include reporting of results and *in vivo* and *in vitro* conditions that may alter results.

A guideline for global application developed through the NCCLS consensus process.



NCCLS...

Serving the World's Medical Science Community Through Voluntary Consensus

NCCLS is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. NCCLS is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, NCCLS provides an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

An NCCLS document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The NCCLS voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most NCCLS documents are subject to two levels of consensus—"proposed" and "approved." Depending on

the need for field evaluation or data collection, documents may also be made available for review at an intermediate (i.e., "tentative") consensus level.

Proposed An NCCLS consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Tentative A tentative standard or guideline is made available for review and comment only when a recommended method has a well-defined need for a field evaluation or when a recommended protocol requires that specific data be collected. It should be reviewed to ensure its utility.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

NCCLS standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following NCCLS's established consensus procedures. Provisions in NCCLS standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the NCCLS committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any NCCLS document. Address comments to the NCCLS Executive Offices, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in NCCLS projects. Please contact the NCCLS Executive Offices for additional information on committee participation.

Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition

Abstract

Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition (NCCLS document H30-A2) is a performance guideline for laboratory and/or clinical healthcare professionals responsible for the routine performance of fibrinogen assays. This guideline describes a technique, based on the method described by Clauss,¹ that is practical, precise, and widely used in the clinical laboratory. Preanalytical and analytical factors and conditions that may alter results are discussed.

NCCLS. *Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition*. NCCLS document H30-A2 (ISBN 1-56238-439-2). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2001.

THE NCCLS consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of NCCLS documents. Current editions are listed in the *NCCLS Catalog*, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the *NCCLS Catalog*, contact the NCCLS Executive Offices. Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: exoffice@nccls.org; Website: www.nccls.org

H30-A2
ISBN 1-56238-439-2
ISSN 0273-3099

Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition

Volume 21 Number 18

Charles F. Arkin, M.D.
Dorothy M. Adcock, M.D.
H. James Day, M.D.
James J. Carroll, Ph.D.
J. Heinrich Joist, M.D., Ph.D.
Jane G. Lenahan
Richard A. Marlar, Ph.D.
Douglas A. Triplett, M.D.



This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without written permission from NCCLS, except as stated below.

NCCLS hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document's text.

Reproduced with permission, from NCCLS publication H30-A2—*Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition* (ISBN 1-56238-439-2). Copies of the current edition may be obtained from NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from NCCLS by written request. To request such permission, address inquiries to the Executive Director, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Copyright ©2001. The National Committee for Clinical Laboratory Standards.

Suggested Citation

(NCCLS. *Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition*. NCCLS document H30-A2 [ISBN 1-56238-439-2]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2001.)

Proposed Guideline

September 1982

Tentative Guideline

July 1991

Approved Guideline

February 1994

Approved Guideline—Second Edition

November 2001

ISBN 1-56238-439-2

ISSN 0273-3099

Committee Membership

Area Committee on Hematology

Eugene L. Gottfried, M.D.
Chairholder

San Francisco General Hospital
San Francisco, California

Charles F. Arkin, M.D.
Vice-Chairholder

Boston University Medical Center
Boston, Massachusetts

Subcommittee on Coagulation

Charles F. Arkin, M.D.
Chairholder

Boston University Medical Center
Boston, Massachusetts

Dorothy M. Adcock, M.D.

Colorado Permanente Medical Group
Aurora, Colorado

James J. Carroll, Ph.D.

Raritan, New Jersey

H. James Day, M.D.

Temple University Hospital
Philadelphia, Pennsylvania

J. Heinrich Joist, M.D., Ph.D.

St. Louis University Health Sciences Center
St. Louis, Missouri

Jane G. Lenahan

Florham Park, New Jersey

Richard Marlar, Ph.D.

Denver VA Medical Center
Denver, Colorado

Douglas A. Triplett, M.D.

Ball Memorial Hospital
Muncie, Indiana

Advisors

John T. Brandt, M.D.

Eli Lilly & Co.
Indianapolis, Indiana

Jonathan S. Krauss, M.D.

Medical College of Georgia Hospitals and Clinics
Augusta, Georgia

C. Harold Mielke, Jr., M.D., F.A.C.P.

Washington State University
Spokane, Washington

Alvin H. Schmaier, M.D.

University of Michigan Medical Center
Ann Arbor, Michigan

Jamie E. Siegel, M.D.

East Brunswick, New Jersey

David J. Warunek, Ph.D.

BD VACUTAINER Systems
Franklin Lakes, New Jersey

Number 18

NCCLS

Jennifer K. McGeary, M.T.(ASCP), M.S.H.A.
Staff Liaison

NCCLS
Wayne, Pennsylvania

Patrice E. Polgar
Editor

NCCLS
Wayne, Pennsylvania

Donna M. Wilhelm
Assistant Editor

NCCLS
Wayne, Pennsylvania

Active Membership (as of 1 October 2001)

Sustaining Members

Abbott Laboratories
 American Association for
 Clinical Chemistry
 Bayer Corporation
 Beckman Coulter, Inc.
 BD and Company
 bioMérieux, Inc.
 CLMA
 College of American Pathologists
 GlaxoSmithKline
 Nippon Becton Dickinson Co., Ltd.
 Ortho-Clinical Diagnostics, Inc.
 Pfizer Inc
 Roche Diagnostics, Inc.

Professional Members

AISAR-Associazione Italiana per lo
 Studio degli
 American Academy of Family
 Physicians
 American Association for
 Clinical Chemistry
 American Association for
 Respiratory Care
 American Chemical Society
 American Medical Technologists
 American Public Health Association
 American Society for Clinical
 Laboratory Science
 American Society of Hematology
 American Society for Microbiology
 American Society of
 Parasitologists, Inc.
 American Type Culture
 Collection, Inc.
 Asociacion de Laboratorios de Alta
 Complejidad
 Asociación Española Primera de
 Socorros (Uruguay)
 Asociacion Mexicana de
 Bioquímica Clínica A.C.
 Assn. of Public Health Laboratories
 Assoc. Micro. Clinici Italiani-
 A.M.C.L.I.
 Australasian Association of
 Clinical Biochemists
 British Society for Antimicrobial
 Chemotherapy
 CADIME-Camara De Instituciones
 De Diagnostico Medico

Canadian Society for Medical
 Laboratory Science—Société
 Canadienne de Science de
 Laboratoire Médical
 Canadian Society of Clinical
 Chemists
 Clinical Laboratory Management
 Association
 COLA
 College of American Pathologists
 College of Medical Laboratory
 Technologists of Ontario
 College of Physicians and
 Surgeons of Saskatchewan
 Fundación Bioquímica Argentina
 International Association of Medical
 Laboratory Technologists
 International Council for
 Standardization in Haematology
 International Federation of
 Clinical Chemistry
 Italian Society of Clinical
 Biochemistry
 Japan Society of Clinical Chemistry
 Japanese Committee for Clinical
 Laboratory Standards
 Joint Commission on Accreditation
 of Healthcare Organizations
 National Academy of Clinical
 Biochemistry
 National Society for
 Histotechnology, Inc.
 Ontario Medical Association
 Quality Management Program-
 Laboratory Service
 RCPA Quality Assurance Programs
 PTY Limited
 Sociedade Brasileira de Analises
 Clinicas
 Sociedade Brasileira de
 Patologia Clínica
 Sociedad Espanola de Bioquímica
 Clínica y Patología Molecular
 Turkish Society of Microbiology

Government Members

Association of Public Health
 Laboratories
 Armed Forces Institute of Pathology
 BC Centre for Disease Control
 Centers for Disease Control and
 Prevention
 Centers for Medicare & Medicaid
 Services/CLIA Program

Centers for Medicare & Medicaid
 Services
 Chinese Committee for Clinical
 Laboratory Standards
 Commonwealth of Pennsylvania
 Bureau of Laboratories
 Department of Veterans Affairs
 Deutsches Institut für Normung
 (DIN)
 FDA Center for Devices and
 Radiological Health
 FDA Center for Veterinary
 Medicine
 FDA Division of Anti-Infective
 Drug Products
 Iowa State Hygienic Laboratory
 Massachusetts Department of
 Public Health Laboratories
 National Association of Testing
 Authorities – Australia
 National Center of Infectious
 and Parasitic Diseases (Bulgaria)
 National Institute of Standards
 and Technology
 Ohio Department of Health
 Ontario Ministry of Health
 Saskatchewan Health-Provincial
 Laboratory
 Scientific Institute of Public Health;
 Belgium Ministry of Social
 Affairs, Public Health and the
 Environment
 South African Institute for Medical
 Research
 Swedish Institute for Infectious
 Disease Control
 Thailand Department of Medical
 Sciences

Industry Members

AB Biodisk
 Abbott Laboratories
 Abbott Laboratories, MediSense
 Products
 Accumetrics, Inc.
 Agilent Technologies, Inc.
 Ammirati Regulatory Consulting
 Anaerobe Systems
 Assessor
 AstraZeneca
 Aventis
 Avocet Medical, Inc.
 Axis-Shield POC AS
 Bayer Corporation – Elkhart, IN

Bayer Corporation – Tarrytown, NY
 Bayer Corporation – West Haven, CT
 Bayer Medical Ltd.
 BD
 BD Biosciences – San Jose, CA
 BD Consumer Products
 BD Diagnostic Systems
 BD Italia S.P.A.
 BD VACUTAINER Systems
 Beckman Coulter, Inc.
 Beckman Coulter, Inc. Primary Care Diagnostics
 Beckman Coulter K.K. (Japan)
 Bio-Development SRL
 Bio-Inova Life Sciences International
 Bio-Inova Life Sciences North America
 BioMedia Laboratories Sdn Bhd
 bioMérieux, Inc.
 Biometrology Consultants
 Bio-Rad Laboratories, Inc.
 Bio-Rad Laboratories, Inc. - France
 Biotest AG
 Bristol-Myers Squibb Company
 Canadian External Quality Assessment Laboratory
 Capital Management Consulting, Inc.
 Checkpoint Development Inc.
 Clinical Design Group Inc.
 Clinical Laboratory Improvement Consultants
 COBE Laboratories, Inc.
 Community Medical Center (NJ)
 Control Lab (Brazil)
 Copan Diagnostics Inc.
 Cosmetic Ingredient Review
 Cubist Pharmaceuticals
 Cytometrics, Inc.
 Dade Behring Inc. - Deerfield, IL
 Dade Behring Inc. - Glasgow, DE
 Dade Behring Inc. - Marburg, Germany
 Dade Behring Inc. - Sacramento, CA
 Dade Behring Inc. - San Jose, CA
 DAKO A/S
 Diagnostic Products Corporation
 Eiken Chemical Company, Ltd.
 Enterprise Analysis Corporation
 Fort Dodge Animal Health
 General Hospital Vienna (Austria)
 Gen-Probe
 GlaxoSmithKline
 Greiner Bio-One Inc.
 Health Systems Concepts, Inc.
 Helena Laboratories

Home Diagnostics, Inc.
 Immunicon Corporation
 I-STAT Corporation
 International Technidyne Corporation
 Kendall Sherwood-Davis & Geck
 LAB-Interlink, Inc.
 Labtest Diagnostica S.A.
 LifeScan, Inc. (a Johnson & Johnson Company)
 Lilly Research Laboratories
 Medical Device Consultants, Inc.
 Medtronic, Inc.
 Merck & Company, Inc.
 mvi Sciences (MA)
 Nabi
 Neometrics is.
 Nichols Institute Diagnostics (Div. of Quest Diagnostics, Inc.)
 Nissui Pharmaceutical Co., Ltd.
 Nippon Becton Dickinson Co., Ltd.
 Norfolk Associates, Inc.
 Organon Teknika Corporation
 Ortho-Clinical Diagnostics, Inc. (Raritan, NJ)
 Ortho-Clinical Diagnostics, Inc. (Rochester, NY)
 Oxoid Inc.
 Pfizer Inc
 Pharmacia Corporation
 Powers Consulting Services
 Premier Inc.
 Procter & Gamble Pharmaceuticals, Inc.
 The Product Development Group
 Quintiles, Inc.
 Radiometer America, Inc.
 Radiometer Medical A/S
 David G. Rhoads Associates, Inc.
 Roche Diagnostics GmbH
 Roche Diagnostics, Inc.
 Roche Laboratories (Div. Hoffmann-La Roche Inc.)
 The R.W. Johnson Pharmaceutical Research Institute
 Sarstedt, Inc.
 Carl Schaper
 Schering Corporation
 Schleicher & Schuell, Inc.
 Second Opinion
 Showa Yakuhin Kako Company, Ltd.
 Streck Laboratories, Inc.
 SurroMed, Inc.
 Sysmex Corporation (Japan)
 Sysmex Corporation (Long Grove, IL)
 The Toledo Hospital (OH)

Trek Diagnostic Systems, Inc.
 Vetoquinol S.A.
 Visible Genetics, Inc.
 Vysis, Inc.
 Wallac Oy
 Wyeth-Ayerst
 Xyletech Systems, Inc.
 YD Consultant
 YD Diagnostics (Seoul, Korea)

Trade Associations

AdvaMed
 Association of Medical Diagnostic Manufacturers
 Japan Association Clinical Reagents Ind. (Tokyo, Japan)
 Medical Industry Association of Australia

Associate Active Members

20th Medical Group (SC)
 67th CSH Wuerzburg, GE (NY)
 Academisch Ziekenhuis-VUB (Belgium)
 Acadiana Medical Laboratories, LTD (LA)
 Adena Regional Medical Center (OH)
 Advocate Laboratories (IL)
 The Aga Khan Hospital & Medical College, Karachi (Pakistan)
 Akershus Central Hospital and AFA (Norway)
 Albany Medical Center Hospital (NY)
 Albemarle Hospital (NC)
 Allegheny General Hospital (PA)
 Allegheny University of the Health Sciences (PA)
 Allina Laboratories (MN)
 Alton Ochsner Medical Foundation (LA)
 American Medical Laboratories (VA)
 Arkansas Department of Health
 ARUP Laboratories (UT)
 ARUP at University Hospital (UT)
 Armed Forces Research Institute of Medical Science (APO, AP)
 Aurora Consolidated Laboratories (WI)
 Azienda Ospedale Di Lecco (Italy)
 Bay Medical Center (MI)
 Baystate Medical Center (MA)

Bbguas Duzen Laboratories (Turkey)	Dynacare Memorial Hermann Laboratory Services (TX)	Huddinge University Hospital (Sweden)
Bo Ali Hospital (Iran)	E.A. Conway Medical Center (LA)	Hurley Medical Center (MI)
Bonnyville Health Center (Alberta, Canada)	Eastern Maine Medical Center	Indiana State Board of Health
British Columbia Cancer Agency (Vancouver, BC, Canada)	East Side Clinical Laboratory (RI)	Indiana University
Broward General Medical Center (FL)	Elyria Memorial Hospital (OH)	Instituto Scientifico HS. Raffaele (Italy)
Calgary Laboratory Services	Emory University Hospital (GA)	International Health Management Associates, Inc. (IL)
Carilion Consolidated Laboratory (VA)	Esoterix Center for Infectious Disease (TX)	Jackson Memorial Hospital (FL)
Carolinas Medical Center (NC)	Fairfax Hospital (VA)	Jersey Shore Medical Center (NJ)
Cathay General Hospital (Taiwan)	Fairview-University Medical Center (MN)	John F. Kennedy Medical Center (NJ)
CB Healthcare Complex (Sydney, NS, Canada)	Florida Hospital East Orlando	John Peter Smith Hospital (TX)
Central Texas Veterans Health Care System	Foothills Hospital (Calgary, AB, Canada)	Kadlec Medical Center (WA)
Centre Hospitalier Regional del la Citadelle (Belgium)	Fort St. John General Hospital (Fort St. John, BC, Canada)	Kaiser Permanente Medical Care (CA)
Centro Diagnostico Italiano (Milano, Italy)	Fox Chase Cancer Center (PA)	Kaiser Permanente (MD)
Champlain Valley Physicians Hospital (NY)	Franklin Square Hospital Center (MD)	Kantonsspital (Switzerland)
Chang Gung Memorial Hospital (Taiwan)	Fresenius Medical Care/Spectra East (NJ)	Kenora-Rainy River Regional Laboratory Program (Ontario, Canada)
Children's Hospital (LA)	Fresno Community Hospital and Medical Center	Kern Medical Center (CA)
Children's Hospital (NE)	Frye Regional Medical Center (NC)	Kimball Medical Center (NJ)
Children's Hospital & Clinics (MN)	Gambro Healthcare Laboratory Services (FL)	King Fahad National Guard Hospital (Saudi Arabia)
Children's Hospital King's Daughters (VA)	GDS Technology, Inc (IN)	King Faisal Specialist Hospital (Saudi Arabia)
Children's Hospital Medical Center (Akron, OH)	Geisinger Medical Center (PA)	King Khalid National Guard Hospital (Saudi Arabia)
Children's Hospital of Philadelphia (PA)	Grady Memorial Hospital (GA)	Kings County Hospital Center (NY)
Clarian Health-Methodist Hospital (IN)	Guthrie Clinic Laboratories (PA)	King's Daughters Medical Center (KY)
Clendo Lab (Puerto Rico)	Hahnemann University Hospital (PA)	Klinični Center (Slovenia)
CLSI Laboratories (PA)	Harris Methodist Erath County (TX)	LabCorp (NC)
Commonwealth of Kentucky	Harris Methodist Fort Worth (TX)	Laboratories at Bonfils (CO)
CompuNet Clinical Laboratories (OH)	Hartford Hospital (CT)	Laboratoire de Santé Publique du Quebec (Canada)
Covance Central Laboratory Services (IN)	Headwaters Health Authority (Alberta, Canada)	Laboratório Fleury S/C Ltda. (Brazil)
Danville Regional Medical Center (VA)	Health Network Lab (PA)	Laboratory Corporation of America (MO)
DeKalb Medical Center (GA)	Health Partners Laboratories (VA)	LAC and USC Healthcare Network (CA)
Delaware Public Health Laboratory	Health Sciences Centre (Winnipeg, MB, Canada)	Lakeland Regional Medical Center (FL)
Department of Health & Community Services (New Brunswick, Canada)	Heartland Health System (MO)	Lancaster General Hospital (PA)
DesPeres Hospital (MO)	Highlands Regional Medical Center (FL)	Langley Air Force Base (VA)
Detroit Health Department (MI)	Hoag Memorial Hospital Presbyterian (CA)	LeBonheur Children's Medical Center (TN)
Diagnostic Laboratory Services, Inc. (HI)	Holmes Regional Medical Center (FL)	Lewis-Gale Medical Center (VA)
Duke University Medical Center (NC)	Holy Spirit Hospital (PA)	Libero Instituto Univ. Campus BioMedico (Italy)
Durham Regional Hospital (NC)	Holzer Medical Center (OH)	Long Beach Memorial Medical Center (CA)
Dynacare Laboratories - Eastern Region (Ottawa, ON, Canada)	Hospital for Sick Children (Toronto, ON, Canada)	Louisiana State University Medical Center
	Hospital Israelita Albert Einstein (Brazil)	Maccabi Medical Care and Health Fund (Israel)
	Hospital Sousa Martins (Portugal)	
	Hotel Dieu Hospital (Windsor, ON, Canada)	

Magee Womens Hospital (PA)	North Shore – Long Island Jewish Health System Laboratories (NY)	St. Boniface General Hospital (Winnipeg, Canada)
Magnolia Regional Health Center (MS)	Northridge Hospital Medical Center (CA)	St. Elizabeth Hospital (NJ)
Manitoba Health (Winnipeg, Canada)	Northwestern Memorial Hospital (IL)	St-Eustache Hospital (Quebec, Canada)
Martin Luther King/Drew Medical Center (CA)	Ohio Valley Medical Center (WV)	St. John Hospital and Medical Center (MI)
Massachusetts General Hospital (Microbiology Laboratory)	O.L. Vrouwziekenhuis (Belgium)	St. John Regional Hospital (St. John, NB, Canada)
MDS Metro Laboratory Services (Burnaby, BC, Canada)	Ordre professionnel des technologistes médicaux du Québec	St. Joseph Hospital (NE)
Medical College of Virginia Hospital	Ospedali Riuniti (Italy)	St. Joseph's Hospital – Marshfield Clinic (WI)
Medicare/Medicaid Certification, State of North Carolina	The Ottawa Hospital (Ottawa, ON, Canada)	St. Joseph's Medical Center (CA)
Memorial Medical Center (IL)	Our Lady of Lourdes Hospital (NJ)	St. Luke's Regional Medical Center (IA)
Memorial Medical Center (LA)	Our Lady of the Resurrection Medical Center (IL)	St. Mark's Hospital (UT)
Jefferson Davis Hwy	Pathology and Cytology Laboratories, Inc. (KY)	St. Mary Medical Center (IN)
Memorial Medical Center (LA)	The Permanente Medical Group (CA)	St. Mary of the Plains Hospital (TX)
Napoleon Avenue	Piedmont Hospital (GA)	St. Mary's Hospital & Medical Center (CO)
Mescalero Indian Hospital (NM)	Pocono Hospital (PA)	St. Paul's Hospital (Vancouver, BC, Montreal)
Methodist Hospitals of Memphis (TN)	Polly Ryon Memorial Hospital (TX)	St. Vincent Medical Center (CA)
MetroHealth Medical Center (OH)	Presbyterian Hospital of Dallas (TX)	Ste. Justine Hospital (Montreal, PQ, Canada)
Michigan Department of Community Health	Prodia Clinical Laboratory (Indonesia)	Salina Regional Health Center (KS)
Monmouth Medical Center (NJ)	Providence Health System (OR)	San Francisco General Hospital (CA)
Monte Tabor – Centro Italo - Brasileiro de Promocao (Brazil)	Providence Seattle Medical Center (WA)	Santa Cabrini Hospital (Montreal, PQ Canada)
Montreal Children's Hospital (Canada)	Queen Elizabeth Hospital (Prince Edward Island, Canada)	Santa Clara Valley Medical Center (CA)
Montreal General Hospital (Canada)	Queensland Health Pathology Services (Australia)	Seoul Nat'l University Hospital (Korea)
Morton Plant Mease Health Care (FL)	Quest Diagnostics Incorporated (CA)	Shanghai Center for the Clinical Laboratory (China)
MRL Pharmaceutical Services, Inc. (VA)	Quintiles Laboratories, Ltd. (GA)	South Bend Medical Foundation (IN)
MRL Reference Laboratory (CA)	Reading Hospital and Medical Center (PA)	Southern California Permanente Medical Group
National Institutes of Health (MD)	Regions Hospital	South Western Area Pathology Service (Australia)
National University Hospital (Singapore)	Reid Hospital & Health Care Services (IN)	Southwest Texas Methodist Hospital
Naval Surface Warfare Center (IN)	Research Medical Center (MO)	Speciality Laboratories, Inc. (CA)
Nebraska Health System	Rex Healthcare (NC)	Stanford Hospital and Clinics (CA)
New Britain General Hospital (CT)	Rhode Island Department of Health Laboratories	State of Washington Department of Health
New England Fertility Institute (CT)	Riyadh Armed Forces Hospital (Saudi Arabia)	Stormont-Vail Regional Medical Center (KS)
New England Medical Center Hospital (MA)	Royal Columbian Hospital (New Westminster, BC, Canada)	Sun Health-Boswell Hospital (AZ)
New York Hospital Medical Center of Queens	Sacred Heart Hospital (MD)	Sunrise Hospital and Medical Center (NV)
New York State Department of Health	Saint Mary's Regional Medical Center (NV)	T.A. Sourasky Medical Center (Israel)
NorDx (ME)	St. Alexius Medical Center (ND)	Tampa General Hospital (FL)
North Carolina State Laboratory of Public Health	St. Anthony Hospital (CO)	Temple University Hospital (PA)
Northern Indiana Education Foundation	St. Barnabas Medical Center (NJ)	

Tenet Odessa Regional Hospital (TX)	University of Colorado Health Science Center	VA Outpatient Clinic (OH)
The Toledo Hospital (OH)	University of Chicago Hospitals (IL)	Vejle Hospital (Denmark)
Touro Infirmary (LA)	University of Florida	Viridae Clinical Sciences, Inc. (Vancouver, BC, Canada)
Trident Regional Medical Center (SC)	University of Illinois at Chicago	Washoe Medical Center Laboratory (NV)
Tripler Army Medical Center (HI)	University of the Ryukyus (Japan)	Watson Clinic (FL)
Truman Medical Center (MO)	University of Texas M.D. Anderson Cancer Center	Wilford Hall Medical Center (TX)
UCSF Medical Center (CA)	University of Virginia Medical Center	William Beaumont Hospital (MI)
UNC Hospitals (NC)	University of Washington	Williamsburg Community Hospital (VA)
University Hospital (Gent) (Belgium)	UPMC Bedford Memorial (PA)	Winn Army Community Hospital (GA)
University Hospitals of Cleveland (OH)	UZ-KUL Medical Center (Belgium)	Wishard Memorial Hospital (IN)
The University Hospitals (OK)	VA (Dayton) Medical Center (OH)	Yonsei University College of Medicine (Korea)
University of Alabama-Birmingham Hospital	VA (Denver) Medical Center (CO)	York Hospital (PA)
University of Alberta Hospitals (Canada)	VA (San Diego) Medical Center (CA)	Zale Lipshy University Hospital (TX)
	VA (Tuskegee) Medical Center (AL)	

OFFICERS

BOARD OF DIRECTORS

F. Alan Andersen, Ph.D., President Cosmetic Ingredient Review	Susan Blonshine, RRT, RPFT, FAARC TechEd	Tadashi Kawai, M.D., Ph.D. International Clinical Pathology Center
Donna M. Meyer, Ph.D., President Elect CHRISTUS Health	Wayne Brinster BD	J. Stephen Kroger, M.D., FACP COLA
Emil Voelkert, Ph.D. Secretary Roche Diagnostics GmbH	Kurt H. Davis, FCSMLS, CAE Canadian Society for Medical Laboratory Science	Gary L. Myers, Ph.D. Centers for Disease Control and Prevention
Gerald A. Hoeltge, M.D. Treasurer The Cleveland Clinic Foundation	Robert L. Habig, Ph.D. Molecular Diagnostics, Inc.	Barbara G. Painter, Ph.D. Bayer Corporation
William F. Koch, Ph.D., Immediate Past President National Institute of Standards and Technology	Thomas L. Hearn, Ph.D. Centers for Disease Control and Prevention	Ann M. Willey, Ph.D., J.D. New York State Department of Health
John V. Bergen, Ph.D., Executive Director	Carolyn D. Jones, J.D., M.P.H. AdvaMed	Judith A. Yost, M.A., M.T.(ASCP) Centers for Medicare & Medicaid Services

Contents

Abstract	i
Committee Membership.....	v
Active Membership.....	vii
Foreword	xv
1 Introduction	1
2 Scope	1
3 Standard Precautions	1
4 Definitions.....	1
5 Principle	2
6 Equipment	2
6.1 Containers	2
6.2 Delivery Systems	2
6.3 Heating Block	2
7 Specimen Handling	3
7.1 Patient Information	3
7.2 Specimen Collection, Transportation, Processing, and Storage	3
7.3 Post-test Specimen Management	3
8 Reagents	3
8.1 Commercial Reagents	3
8.2 Non-Commercial Reagents	3
9 Reference Curve.....	4
10 Procedure.....	6
11 Test Result Management.....	6
12 Considerations in Performing the Fibrinogen Assay.....	7
12.1 Manufacturers' Instructions	7
12.2 Water.....	7
12.3 Cleaning	7
12.4 Temperature	7
12.5 End Point Determination.....	7
12.6 Quality Control	7
12.7 Reference Interval	7
13 Sources of Preanalytical Error.....	8
13.1 Inappropriate Specimen Collection.....	8
14 Sources of Analytical Error	8

Contents (Continued)

14.1	Inappropriate Thrombin Preparation.....	8
14.2	Incorrect Conditions.....	8
14.3	Paraproteins.....	8
14.4	Bovine Thrombin Antibodies	9
14.5	Fibrin/Fibrinogen Degradation Products (FDP).....	9
14.6	Heparin.....	9
14.7	Dysfibrinogenemia.....	9
	References	10
	Summary of Comments and Subcommittee Responses	11
	Summary of Delegate Comments and Subcommittee Responses	12
	Related NCCLS Publications	15

Foreword

One of the major physiological roles of the coagulation system is to stop the loss of blood by generating a fibrin meshwork at the site of trauma or injury by converting the plasma glycoprotein fibrinogen to the fibrin polymer mesh. Numerous pathological conditions can induce decreased levels of fibrinogen rendering the coagulation system unable to generate sufficient fibrin to halt the blood loss. Increased levels of fibrinogen have been associated with cardiovascular disease and thrombosis. Decreased or increased levels of fibrinogen are clinically relevant and must be accurately determined. Laboratories should establish a normal reference interval for fibrinogen measurements. Generally, the normal reference interval is 150 to 350 mg/dL (1.5 to 3.5 g/L).

Fibrinogen, a β -globulin, is deficient in congenital afibrinogenemia and hypofibrinogenemia; in some cases of dysfibrinogenemia; and in a variety of acquired states, such as disseminated intravascular coagulation, systemic hyperfibrinolysis, severe hepatic dysfunction, and after treatment with L-asparaginase or sodium valproate. Spontaneous bleeding is usually not seen in patients with selected hypofibrinogenemia, i.e., fibrinogen levels of 50 to 100 mg/dL (0.5 to 1.0 g/L); however with certain types of hemostatic stress (surgery, trauma) bleeding may occur at levels up to 100 mg/dL (1.0g/L).

Fibrinogen is an acute phase reactant (i.e., a variety of physiologic stimuli or stresses such as pregnancy, inflammatory states, or estrogen use cause elevation of the plasma fibrinogen). Sustained progressive increases in fibrinogen within the upper 50th percentile of the normal reference interval or persistently elevated fibrinogen levels have increased risk of arterial and venous thrombosis (a prethrombotic state or a hypercoagulable state). Elevated fibrinogen levels have been implicated as a possible risk factor for the development of arterial and venous thrombotic complications.²⁻¹¹ Consequently, fibrinogen levels may be more widely used in the future for the assessment of the risk of developing thrombotic complications.

A number of assays of plasma fibrinogen have been described which are based on measurements of total clottable fibrinogen by protein assay,^{7,8} changes in turbidity or light scattering,⁹ salt precipitation,¹⁰ and fibrinogen antigen by various immunologic methods.^{2,11}

This document also describes a specific technique for the determination of fibrinogen concentration based on the Clauss thrombin clotting rate assay.¹ This assay is practical, precise, and widely used in the clinical laboratory. This document is primarily directed toward laboratory and/or clinical personnel responsible for obtaining and processing blood specimens, performing the fibrinogen assay and quality control procedures, and reporting fibrinogen assay results. It is also intended as a guide for manufacturers of the reagents and instruments. Preanalytical and analytical factors and conditions that may alter results are discussed.

Other international standards procedures have been established for determination of fibrinogen in plasma. This guideline was separately from standards for fibrinogen determination prepared by the Deutsches Institut für Normung (DIN).^{12,13} On comparison, the documents appear to be essentially the same. Some differences do occur based on available and standard reagents. Use of either should allow determination of fibrinogen concentration. NCCLS will work toward harmonization in the next revision of H30.

The Quality System Approach

NCCLS subscribes to a quality system approach in the development of standards and guidelines, which facilitates project management; aids in defining document structure; and provides a process to identify needed documents through a gap analysis. The approach is based on the model presented in the most current edition of NCCLS document GP26—*A Quality System Model for Health Care*.

Foreword (Continued)

The quality system approach applies a core set of “quality system essentials,” basic to any organizational process, to all operations in the healthcare service’s path of workflow. The quality system essentials are: organization; personnel; equipment; purchasing and inventory; process control; documents and records; occurrence management; internal assessment; process improvement; service and satisfaction; facilities and safety; and information management. The path of workflow for the clinical laboratory consists of three process areas: preanalytical; analytical; postanalytical.

NCCLS document H30-A2—*Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition* describes the preanalytical and analytical aspects of the path of workflow for the clinical laboratory by specifically providing guidance on the collection, transportation, handling, and storage of the specimen or sample and on performing fibrinogen assays in the laboratory.

Key Words

Afibrinogenemia, Clauss method, disseminated intravascular coagulation (DIC), dysfibrinogenemia, fibrin, fibrinogen, hypofibrinogenemia

Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition

1 Introduction

This document specifies a technique to assay fibrinogen in plasma, based on the method of Clauss.¹

2 Scope

H30-A2 contains guidelines for the collection, transportation, handling, and storage of blood specimens or plasma samples and general guidelines for performing the fibrinogen assay by the Clauss method.¹ It is primarily directed toward laboratory and/or clinical personnel responsible for obtaining and processing blood specimens, performing the fibrinogen assay and quality control procedures, and reporting fibrinogen assay results. It is also intended as a guide for manufacturers of the reagents and instruments. The guideline does not cover prothrombin-time (PT)-derived fibrinogen determination which can be performed using various automated coagulation instruments.¹⁴

3 Standard Precautions

Because it is often impossible to know what might be infectious, all human blood specimens are to be treated as infectious and handled according to “standard precautions.” Standard precautions are new guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of any pathogen and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-borne pathogens. Standard precaution and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (*Guideline for Isolation Precautions in Hospitals*. Infection Control and Hospital Epidemiology. CDC. 1996;Vol 17;1:53-80.), [MMWR 1987;36(suppl 2S):2S-18S] and (MMWR 1988;37:377-382, 387-388). For specific precautions for preventing the laboratory transmission of blood-borne infection from laboratory instruments and materials; and recommendations for the management of blood-borne exposure, refer to NCCLS document M29—*Protection of Laboratory Workers from Instrument Biohazards and Infectious Disease Transmitted by Blood, Body Fluids, and Tissue*.

4 Definitions^a

Control (plasma), *n* - A batch of citrated plasma used to monitor the stability of the laboratory test system, which includes reagents, instruments, reconstituting and diluting fluids, and pipettes; **NOTES:** a) “Normal control plasma” gives test results within the range of the reference interval; b) “Abnormal control plasmas” for factor assays should contain factor concentrations below the reference interval values due to abnormally low factor concentrations; c) If factors are clinically elevated, the “abnormal control plasma” should contain factor concentrations above the reference interval; d) Normal and abnormal control plasmas may be prepared in the laboratory or obtained commercially.

Reference curve, *n* - A line, typically a straight line, that defines the quantitative relationship between an independent variable and a dependent variable; **NOTE:** From this line the observed output of an analytic procedure (e.g., APTT test) can be converted to the units of measurement of the analyte of interest (e.g., coagulation factor activity).

^a Some of these definitions are found in NCCLS document NRSCL8—*Terminology and Definitions for Use in NCCLS Documents*. For complete definitions and detailed source information, please refer to the most current edition of that document.